<scp>ALDH2</scp> Mediated Ferroptosis Regulation in Ischemia–Reperfusion Injury

Ischemia-reperfusion injury (IRI) is a common complication in diverse clinical settings, including myocardial infarction, stroke, organ transplantation and major surgery. Its pathological core lies in the metabolic disruption caused by blood flow cessation, followed by oxidative stress, inflammatory cascades and cell death upon reperfusion. Aldehyde dehydrogenase 2 (ALDH2), a mitochondrial enzyme best known for its role in aldehyde detoxification, has emerged as an important endogenous protective factor in IRI. ALDH2 limits the accumulation of toxic lipid peroxidation products, preserves mitochondrial function and attenuates oxidative and inflammatory damage in multiple organs. In parallel, ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has been increasingly recognised as a key execution pathway in IRI. Increasing evidence suggests a close intersection between ALDH2 and ferroptosis. This review aims to systematically summarise the interplay between ALDH2 and ferroptosis in IRI, further explore their involvement in other forms of regulated cell death and highlight their points of convergence. Collectively, available data suggest that targeting ALDH2 may represent a promising strategy for limiting ferroptosis and reducing tissue damage in IRI.

Authors

Institutions

Publication Details

Journal
Journal of Cellular and Molecular Medicine
Published
2026-03-01
DOI
https://doi.org/10.1111/jcmm.71072
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ALDH2 Mediated Ferroptosis Regulation in Ischemia–Reperfusion Injury

Liang Han, Wen Zhai
Journal of Cellular and Molecular Medicine
Ferroptosis and cancer prognosis
article

ALDH2 Mediated Ferroptosis Regulation in Ischemia–Reperfusion Injury

Liang Han, Wen Zhai
article en

Abstract

Ischemia-reperfusion injury (IRI) is a common complication in diverse clinical settings, including myocardial infarction, stroke, organ transplantation and major surgery. Its pathological core lies in the metabolic disruption caused by blood flow cessation, followed by oxidative stress, inflammatory cascades and cell death upon reperfusion. Aldehyde dehydrogenase 2 (ALDH2), a mitochondrial enzyme best known for its role in aldehyde detoxification, has emerged as an important endogenous protective factor in IRI. ALDH2 limits the accumulation of toxic lipid peroxidation products, preserves mitochondrial function and attenuates oxidative and inflammatory damage in multiple organs. In parallel, ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has been increasingly recognised as a key execution pathway in IRI. Increasing evidence suggests a close intersection between ALDH2 and ferroptosis. This review aims to systematically summarise the interplay between ALDH2 and ferroptosis in IRI, further explore their involvement in other forms of regulated cell death and highlight their points of convergence. Collectively, available data suggest that targeting ALDH2 may represent a promising strategy for limiting ferroptosis and reducing tissue damage in IRI.

Journal of Cellular and Molecular MedicineVol. 30(6)
Hangzhou Medical College (CN)
Good health and well-being
Openalex Percentile: Top 7%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<scp>ALDH2</scp> Mediated Ferroptosis Regulation in Ischemia–Reperfusion Injury — Liang Han, Wen Zhai · Journal of Cellular and Molecular Medicine (2026) | TGRS Research Map | TGRS